[HTML][HTML] Characterization and prognosis significance of JAK2 (V617F), MPL, and CALR mutations in Philadelphia-negative myeloproliferative neoplasms
R Singdong, T Siriboonpiputtana… - Asian Pacific journal …, 2016 - ncbi.nlm.nih.gov
Background: The discovery of somatic acquired mutations of JAK2 (V617F) in Philadelphia-
negative myeloproliferative neoplasms (Ph-negative MPNs) including polycythemia vera …
negative myeloproliferative neoplasms (Ph-negative MPNs) including polycythemia vera …
Detection of driver mutations in plasma cell–free nucleic acids in differentiated thyroid neoplasm
S Dutta, S Tarafdar, P Mukhopadhyay… - European Journal of …, 2023 - academic.oup.com
Importance This proof-of-concept paper demonstrates that driver mutations can be detected
in plasma in differentiated thyroid tumors, and we were able to detect mutations in upto 80 …
in plasma in differentiated thyroid tumors, and we were able to detect mutations in upto 80 …
[HTML][HTML] Prevalence of the Janus kinase 2 V617F mutation in Philadelphia‑negative myeloproliferative neoplasms in a Portuguese population
AP Azevedo, SN Silva, A Reichert… - Biomedical …, 2017 - spandidos-publications.com
Myeloproliferative neoplasms (MPNs) result from the malignant transformation of a
hematopoietic stem‑cell (HSC), leading to abnormal amplification and proliferation of …
hematopoietic stem‑cell (HSC), leading to abnormal amplification and proliferation of …
Correlation between JAK2 allele burden and pulmonary arterial hypertension and hematological parameters in Philadelphia negative JAK2 positive myeloproliferative …
MM Mattar, MAK Morad, NM El Husseiny, NH Ali… - Annals of …, 2016 - Springer
Myeloproliferative neoplasms are characterized by a common stem cell-derived clonal
proliferation, but are phenotypically diverse. JAK2 is mutated (V617F) in more than 90% of …
proliferation, but are phenotypically diverse. JAK2 is mutated (V617F) in more than 90% of …
Non-receptor tyrosine kinases role and significance in hematological malignancies
A Azevedo, S Silva, J Rueff - Tyrosine Kinases as Druggable …, 2019 - books.google.com
This chapter presents a review about non-receptor tyrosine kinases, their structure,
mechanisms of action and physiopathology, and how they are regulated and interact with …
mechanisms of action and physiopathology, and how they are regulated and interact with …
Characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident
Myeloproliferative neoplasms (MPNs) driver mutations are usually found in JAK2, MPL, and
CALR genes; however, 10%‐15% of cases are triple negative (TN). A previous study …
CALR genes; however, 10%‐15% of cases are triple negative (TN). A previous study …
The impact of JAK2V617F mutation on Philadelphia-negative myeloproliferative neoplasms
E Şahin, İY HİNDİLERDEN… - Turkish journal of …, 2022 - journals.tubitak.gov.tr
Background/aim: JAK2V617F mutation is expressed in almost all polycthemia vera (PV),
55% of essential thrombocythemia (ET), and 65% of primary myelofibrosis (PMF) patients …
55% of essential thrombocythemia (ET), and 65% of primary myelofibrosis (PMF) patients …
[HTML][HTML] The evaluation of patients with essential thrombocythemia in terms of risk of thrombosis
C Sunu, AK Gunes, GK Akat, Y Kalpakci… - Revista da Associação …, 2021 - SciELO Brasil
SUMMARY OBJECTIVE: The aim of this study was to compare the incidence of factors
associated with an increased risk of thrombosis in patients with essential thrombocythemia …
associated with an increased risk of thrombosis in patients with essential thrombocythemia …
[HTML][HTML] Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative …
Background Calreticulin (CALR) gene mutations are currently recommended as biomarkers
in diagnosis of patients with myeloproliferative neoplasms (MPN) with Jak2 V617F negative …
in diagnosis of patients with myeloproliferative neoplasms (MPN) with Jak2 V617F negative …
Association of JAK2 Haplotype GGCC_46/1 with the Response to Onco-Drug in MPNs Patients Positive for JAK2V617F Mutation
M Perrone, S Sergio, A Tarantino, G Loglisci, R Matera… - 2024 - preprints.org
Abstract JAK2 V617F is a somatic mutation associated with myeloproliferative neoplasm
(MPN): polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis …
(MPN): polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis …